Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy

Summary: Inhibitors of neprilysin improve glycemia in patients with heart failure and type 2 diabetes (T2D). The effect of weight loss by diet, surgery, or pharmacotherapy on neprilysin activity (NEPa) is unknown. We investigated circulating NEPa and neprilysin protein concentrations in obesity, T2D...

Cijeli opis

Bibliografski detalji

Glavni autori:	Sasha A.S. Kjeldsen, Lise L. Gluud, Mikkel P. Werge, Julie S. Pedersen, Flemming Bendtsen, Kleopatra Alexiadou, Tricia Tan, Signe S. Torekov, Eva W. Iepsen, Nicole J. Jensen, Michael M. Richter, Jens P. Goetze, Jørgen Rungby, Bolette Hartmann, Jens J. Holst, Birgitte Holst, Joachim Holt, Finn Gustafsson, Sten Madsbad, Maria S. Svane, Kirstine N. Bojsen-Møller, Nicolai J. Wewer Albrechtsen
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2023-11-01
Serija:	iScience
Teme:	Health sciences Obesity medicine Diabetology
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2589004223022678
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!